https://www.selleckchem.com/products/c-75.html
Combining different cancer treatments represents a promising strategy to improve the therapeutic outcome for lung cancer patients with or without druggable gene alterations. We previously developed a polyethylene glycol-based (PEG-based) immunostimulatory nanocarrier (PEG -Fmoc-NLG919) which can efficiently co-deliver an indoleamine 2,3-dioxygenase-1 (IDO1) inhibitor and the chemotherapeutic agent, paclitaxel. This method was found to improve cancer therapy by simultaneously performing immuno- and chemo-therapy. However, whether this nanoc
Like
Comment
Share
